Maternal Subclinical Hyperthyroidism and Adverse Pregnancy Outcomes: A Systematic Review and Meta-analysis of Observational Studies

Sima Nazarpour 1,2, Mina Amiri 2, Razieh Bidhendi Yarandi 3, Fereidoun Azizi 4 and Fahimeh Ramezani Tehrani 2, *

1Department of Midwifery, Varamin-Pishva Branch, Islamic Azad University, Tehran, Iran
2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
4Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: fah.tehrani@gmail.com

Received 2021 November 13; Revised 2022 June 18; Accepted 2022 June 21.

Abstract

Context: Findings from studies evaluating adverse pregnancy outcomes in pregnant women with subclinical hyperthyroidism are conflicting and inconclusive.

Objectives: In this systematic review and meta-analysis, our aim was to evaluate the pooled odds ratio (OR) of adverse pregnancy outcomes in women with subclinical hyperthyroidism, compared to euthyroid women.

Data Sources: Scopus, PubMed (including Medline), and Web of Science databases were systemically searched for regaining published studies to January 2022 examining adverse pregnancy outcomes in women with subclinical hyperthyroidism.

Study Selection: Outcomes of interest were classified into seven composite outcomes, including hypertensive disorders, preterm delivery, macrosomia/large for gestational age (LGA), pregnancy loss, adverse maternal outcomes, adverse neonatal outcomes, and adverse fetal outcomes.

Data Extraction: In this meta-analysis, both fixed and random effect models were used. Publication bias was also evaluated by Egger test and the funnel plot, and the trim and fill method was conducted in case of a significant result, to adjust the bias.

Results: Of 202 records retrieved through searching databases, 11 studies were selected for the final analyses. There were no significant differences in pooled ORs of hypertensive disorders, preterm delivery, macrosomia/LGA, and pregnancy loss in pregnant women with subclinical hyperthyroidism, compared to the euthyroid controls. The pooled OR of adverse maternal, neonatal, and fetal outcomes in pregnant women with subclinical hyperthyroidism was not statistically significantly different from that of the euthyroid control group.

Conclusions: The current meta-analysis demonstrated that subclinical hyperthyroidism in pregnancy is not related with adverse maternal and fetal outcomes. Therefore, clinicians should be avoided unnecessary treatments for pregnant women with subclinical hyperthyroidism.

Keywords: Subclinical Hyperthyroidism, Pregnancy Outcomes, Systematic Review, Meta-analysis

1. Context

Pregnancy is associated with several changes in maternal thyroid function (1, 2) during various stages of pregnancy, that may cause a significant increase in the prevalence of thyroid disease in pregnant women (2). Accordingly, thyroid disease is one of the most common endocrine disorders during pregnancy (3).

Hyperthyroidism is caused by the hypersecretion of thyroid hormones. Moreover, there is evidence demonstrating that hyperthyroidism is associated with the increased excitability or hyper-metabolism of circulation, digestive system, and nerve (4). Earlier studies have demonstrated that not only overt thyroid dysfunction but also sub-clinical dysfunction can associate with increased risks of adverse maternal and fetal outcomes (3, 5-9). Subclinical hyperthyroidism is defined by low serum thyroid-stimulating hormone (TSH), but normal serum T4 and T3 concentrations (10), which may reflect mild thyroid hormone excess, hypothalamic, or pituitary disease (11).
thyroid dysfunction is relatively common among women of reproductive age and increases with aging (12). Subclinical hyperthyroidism occurs in 0.4 - 1.7% of pregnancies (12-16) and it is more prevalent in parous women in iodine deficiency areas (17, 18).

Despite solid evidence regarding the adverse effect of maternal hyperthyroidism on pregnancy outcomes (2, 16, 19-22), the results of studies conducted on adverse consequences of subclinical hyperthyroidism on pregnancy outcomes are still conflicting and inconclusive (2, 3, 9, 12, 16, 22-25). While some studies reported no significant adverse effect of subclinical hyperthyroidism on pregnancy outcomes (5, 12, 26, 27), others reported protective effects in terms of pregnancy-induced hypertension (12), and improvement of Apgar score (25), and some other ones illustrated adverse effects on preeclampsia and placental abruption (2).

Several previous systematic reviews and meta-analyses have been published on adverse pregnancy outcomes of thyroid dysfunction so far (8, 25, 28-31); however the majority of them have not reported these outcomes specifically for subclinical hyperthyroidism (8, 28, 29). Among those ones that included this subgroup of thyroid dysfunction, various feto-maternal outcomes have not been investigated and only intrauterine growth restriction (IUGR) (25) and low birth weight (LBW) (30) have been reported.

2. Objectives

Accordingly, this systematic review and meta-analysis aimed to investigate the association between subclinical hyperthyroidism and various adverse pregnancy outcomes in pregnant women.

3. Evidence Acquisition

3.1. Study Design

The present study was approved by the ethics committee of the Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences (code: IR.SBMU.ENDOCRINE.REC.1399.073), and the study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Code: CRD42020192583, link: www.crd.york.ac.uk/prospero/#myprospero). The systematic review and meta-analysis became carried out based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (32) and MOOSE guidelines (33).

The PICO question of this study was: in pregnant women with subclinical hyperthyroidism what are adverse pregnancy outcomes, compared to those in the euthyroid group?

3.2. Search Strategy and Study Selection

A comprehensive literature search was conducted using PubMed [including Medline] and Scopus and Web of Sciences databases for retrieving English articles published until January 2022 investigating adverse pregnancy outcomes in women with subclinical hyperthyroidism. Furthermore, to maximize the identify of eligible research, review articles and the reference lists of the included research had been manually evaluated as well.

The following keywords, alone or in combination, had been used for the search: (“subclinical hyperthyroidism” OR “subclinical thyroid dysfunction” OR “subclinical thyroid disorder”) AND (“pregnancy” OR “gestational” OR “maternal” OR “pregnant women”) AND (“adverse pregnancy outcomes” OR “pregnancy outcomes” OR “pregnancy complications” OR “maternal outcome” OR “perinatal outcome” OR “neonatal outcome” OR “infant outcome” OR “miscarriage” OR “pregnancy loss” OR “abortion” OR “stillbirth” OR “fetal death” OR “gestational diabetes” OR “gestational hypertension” OR “preeclampsia” OR “PIH” OR “postpartum hemorrhage” OR “hemorrhage” OR “PPH” OR “Placenta abruption” OR “placenta previa” OR “premature rupture of membrane” OR “PPROM” OR “oligohydramnios” OR “preterm” OR “small for gestational age” OR “Intra uterine growth restriction” OR “IUGR” OR “Low birth weight” OR “LBW” OR “Apgar” OR “fetal distress” OR “neonatal distress” OR “RDS” OR “neonatal death” OR “neonatal mortality” OR “NICU admission” OR “neonatal admission” OR “anomalies” OR “malformation” OR “neonatal *” OR “maternal *” OR “fetal *”)) (Appendix 1).

3.3. Eligibility Criteria, Study Selection, and Data Extraction

In the present meta-analysis, we searched all observational studies (cohort, case-control, and cross-sectional) published in English. Studies have been eligible if they had: (1) A study population including pregnant women with subclinical hyperthyroidism, (2) the pregnant women had not received any treatment, (3) a control group of euthyroid, and (4) evaluated at least one adverse pregnancy outcome, including pregnancy loss (stillbirth, fetal death, abortion, or perinatal mortality), pregnancy-induced hypertension (PIH), preeclampsia or eclampsia, gestational diabetes, obstetrical hemorrhage (PPH, placenta abruption, and placenta previa), preterm delivery, premature rupture of membrane (PROM), preterm premature rupture of the membranes (PPROM), small for gestational age (SGA) or IUGR, low birth weight (LBW), large for gestational age (LGA), macrosomia, malpresentation, respiratory distress syndrome (RDS), fetal distress, low Apgar scores, gestational hypertension, gestational diabetes, obstetric hemorrhage, preterm delivery, premature rupture of membrane, small for gestational age, low birth weight, low Apgar scores, and respiratory distress syndrome.
score, neonatal death, neonatal complication or NICU admission. We have also excluded non-original studies, including case reports, review articles, animal studies, guidelines, commentaries, editorials, meeting abstracts, and letters to the editor, as well as the researches that did not offer accurate and clear data in this regard. Additionally, studies on women with multiple pregnancies and those with no control group were excluded.

The screening of titles, abstracts, and full-text of the retrieved researches was performed independently by two independent authors (FRT and SN) to select eligible studies. The disagreements among the reviewers were resolved through scientific discussions. Information was extracted from each selected article, including study characteristics, such as the first author's name, publication year, country of study, journal name, article title, sample size, study design, population characteristics, pregnancy outcomes, and test results. To prevent extraction and data entry errors, the control checking between the original publications and the final data used in the systematic review was performed by all authors.

3.4. Quality Assessment and Risk of Bias

The modified Newcastle-Ottawa Quality Assessment Scale (NOS) was used to assess the quality of methods and results of the selected studies (34). Two reviewers, who were blinded to the journal name, study's author, and institution, separately evaluated the quality of each study. Information on selection, comparability, and outcomes was evaluated for selected studies. Studies with 3 or 4 stars in the selection domain, 1 or 2 stars in the comparability domain, and 2 or 3 stars in the outcome/exposure domain were considered good quality, studies with 2 stars in the selection domain, 1 or 2 stars in the comparability domain, and 2 or 3 stars in outcome/exposure domain were considered as the fair quality, and studies with 0 or 1 star in selection domain, 0 stars in comparability domain, or 0 or 1 stars in outcome/exposure domain were considered as poor quality.

We have also assessed the risk of bias for all included studies using the Cochrane Collaboration's tool for cohort studies (35) that evaluates seven domains of risk of bias, including adequacy of follow up of cohorts, outcome assessment, the assessment of the presence or absence of prognostic factors, control of prognostic variables, presence of the outcome of interest at the start of the study, the assessment of exposure, and the selection of exposed and non-exposed cohorts. Review authors' judgments were categorized as “definitely No (low risk of bias)”, “probably no”, “definitely yes (high risk of bias)”, and “probably yes” as low risk, high risk, and unclear risk of bias, respectively.

3.5. Outcome Measures

Maternal, neonatal and fetal outcomes of interest were categorized into seven composite outcomes, including (1) hypertensive disorders (PIH, preeclampsia and severe preeclampsia, eclampsia), (2) preterm delivery (preterm < 34 weeks, and < 37 weeks), (3) macrosomia/LGA (macrosomia, large for gestational age), (4) pregnancy loss (abortion, fetal death, fetal loss, still birth, perinatal mortality, medically induced labors), (5) adverse maternal outcomes (PIH, preeclampsia and severe preeclampsia, eclampsia, gestational diabetes, obstetrical hemorrhage (PPH, placenta abruption, and placenta previa)), (6) adverse fetal outcomes (preterm (< 37 weeks and < 34 weeks)), premature rupture of membrane (PROM), preterm premature rupture of the membranes (PPROM), IUGR/small for gestational age (SGA), low birth weight (LBW), very LBW and extremely LBW, macrosomia, LGA, malpresentation, fetal distress, (7) adverse neonatal outcomes (respiratory distress syndrome (RDS), low Apgar score, neonatal death, neonatal complication (hyperbilirubinemia, respiratory distress, sepsis, hypoglycemia, hypothermia, intracranial bleed, Umbilical artery blood pH < 7.0, intraventricular hemorrhage, necrotizing enterocolitis), NICU admission).

3.6. Statistical Analysis

The software package STATA (version 12; STATA Inc., College Station, TX, USA) was applied to perform statistical analyses. Heterogeneity was evaluated using the I-squared ($I^2$) statistics (values above 50% were interpreted as significant heterogeneity) and $P < 0.05$ obtained from the chi-squared test was interpreted as heterogeneity. The funnel plot and Egger test were used for publication bias assessment; the trim and fill method was conducted in case of significant results to adjust the bias.

The random-effects model was employed for heterogeneous findings and for calculating the pooled odds ratio (OR). For all studies, raw data extracted (the number of events in the case and control group) and OR were estimated for them. The inverse variance weighting method was used to calculate the pooled OR.

Furthermore, sensitivity analyses are used for the robustness of the results, any single study with a heterogeneity value out of the range of 95% CI was considered influential and excluded.

$P < 0.05$ was set as the significance level.
Table 1. Characteristics of Studies Included in the Meta-analysis

| First Author     | Country     | Study Design               | Subclinical Hyperthyroidism Definition | Sample Size | Subclinical Hyperthyroidism Prevalence | Outcome                                                                 | Adjusted Factors | Quality Assessment |
|------------------|-------------|----------------------------|----------------------------------------|-------------|---------------------------------------|--------------------------------------------------------------------------|------------------|--------------------|
| Casey (20)       | USA         | Cohort                     | TSH < 0.1 mIU/L and FT4 < 11.96 pmol/L | 25,365      | 4.3 (95% CI: 4.1 - 4.5)               | Pregnancy outcomes; Hypertensive disorders (gestational hypertension, severe preeclampsia), diabetes, placental abruption, weeks of gestation at delivery, cesarean delivery, neonatal outcomes: Birth weight, intrauterine growth restriction, low Apgar score (< 7 at 5 minutes), stillbirth, neonatal death, perinatal mortality | Race and parity  | Good               |
| Mannimos (19)    | Northern Ireland | Prospective Population Based cohort | TSH < 0.35 mIU/L and FT4 < 20.5 pmol/L | 847         | 204 (95% CI: 197 - 211)              | Preterm delivery, birth measurements (birth weight, small for gestational age (SGA), and large for gestational age (LGA) infants, birth length, ponderal index (birth weight/birth length^3), head circumference), Apgar score, perinatal mortality (stillbirth and early neonatal death (< 7 after birth)), neonatal deaths; malformations; presentation at birth, mode of delivery, absolute and relative placental weight, and umbilical cord length | Maternal age and parity | Good               |
| Taghvaei (8)     | Iran        | Cohort                     | TSH < 0.4 mIU/L and normal FT4 level | 500         | 24 (95% CI: 19 - 29)                 | Preterm delivery, preeclampsia, preterm delivery, admission to NICU, birth weight, Apgar score, perinatal mortality | -                | Fair               |
| Sahu (9)         | India       | Prospective cohort         | TSH < 0.1 mIU/L and FT4 < 11.96 pmol/L | 833         | 6 (95% CI: 4.6 - 8.0)                | Maternal outcomes: anemia, preeclampsia, gestational diabetes and obstetric complications, such as abruptio placentae, overall rate of cesarean section, cesarean section for fetal distress, assisted vaginal delivery and postpartum hemorrhage, neonatal outcomes: low birth weight (LBW), prematurity, intrapartum growth restriction (ICG), Apgar score at 1 min, BMI admission and fetal demise | -                | Fair               |
| So (21)          | China       | Prospective population based cohort | TSH < 0.5 mIU/L and FT4 < 20.2 pmol/L | 1087        | 24 (95% CI: 18 - 30)                | Maternal age, parity, and BMI                                           | -                | Good               |
| Wilson (24)      | USA         | Prospective population based cohort | TSH < 0.1 mIU/L and normal FT4 level | 24,883      | 14/24 (6.3%)                         | Hypertension, gestational hypertension, mild pre-eclampsia, or severe preeclampsia, preeclampsia, preterm delivery, low Apgar score, cesarean section, mortality | Maternal age and weight, race, parity                              | Good               |
| Ajmani (3)       | India       | Prospective cohort         | TSH < 0.2 mIU/L, fT4 (0.8 - 2.0 mg/dL) | 400         | 0.75% (95% CI: 0.72 - 0.79)          | Maternal outcomes: anemia, PPHN, abruptio placenta, cesarean section, placental abruption, neonatal outcomes: hyperbilirubinemia, respiratory distress, sepsis, hypothyroidism, hyperthyroidism, intracranial bleed, necrotizing enterocolitis, and early neonatal death | -                | Fair               |
| Rehman (22)      | Iran        | Prospective cohort         | TSH < 0.35 mIU/L and FT4 < 20.5 pmol/L | 500         | 24 (95% CI: 19 - 29)                 | Preterm delivery, preeclampsia, preterm delivery, admission to NICU, birth weight, Apgar score, perinatal mortality | Maternal age, maternal BMI, and pre-eclampsia                        | Good               |
| Zhang (23)       | China       | Prospective cohort         | TSH < 0.15 mIU/L and FT4 > 11.96 pmol/L | 1,703       | 120 (95% CI: 113 - 127)             | Abruptio placenta, eclampsia, placenta previa, placental abruption, PROM, fetal macrosomia, IUGR, breech position, pregnancy delivery | -                | Fair               |
| Zhou (24)        | China       | Cohort                     | TSH < 0.35 mIU/L and FT4 < 20.5 pmol/L | 2,676       | 19 (95% CI: 18 - 21)                | Delivery complications, gestational diabetes, gestational hypertension, intrauterine growth restriction (IUGR), and adverse outcomes: premature birth, VLBW, LBW, birth asphyxia, fetal death, PROM, placental abruption, miscarriage, fetal malformations, mortality | -                | Fair               |
| Aromarosha (10)  | North Macedo- donia | Cohort                     | TSH < 0.35 mIU/L and FT4 < 20.5 pmol/L | 508         | 2 (95% CI: 1.8 - 2.4)               | Preterm births, LBW, VLBW, Apgar score (1 min) < 7                  | -                | Fair               |

4. Results

4.1. Study Selection and Study Characteristics

Of 202 records retrieved through searching databases, 11 studies were included, and all of them had a cohort design (2, 3, 9, 12, 22-24, 36-39). Table 1 summarizes the characteristics of the studies included.

The included studies used a threshold of 0.03 to 0.5 mIU/L for diagnosing subclinical hyperthyroidism (Table 1). A total of 69,862 pregnant women participated in these studies, including 1,418 pregnant women with subclinical hyperthyroidism and 58,502 euthyroid ones. The pooled mean age and BMI (95% CI) of the study population were 26.6 (95% CI: 25.7, 27.4) years and 24.6 (95% CI: 21.7, 27.5) kg/m², respectively.

Figure 1 illustrates the flowchart of the search strategy and the study selection. Figure 2 illustrates the publication bias via funnel plot, bias was observed for various pregnancy outcomes including hypertensive disorders, adverse maternal outcomes, adverse neonatal outcomes, and adverse fetal outcomes. Figures 3 - 9 show the forest plots through random effect for pregnancy outcomes. Sensitivity analyses revealed no source of heterogeneity for any single study (Appendix 2).

4.2. Meta-analysis of Outcomes

Table 2 presents the results of the Egger test, I-squared (%), pooled OR (95% CI), and pooled OR (95% CI) via trim and fill method for pregnancy outcomes in women with subclinical hyperthyroidism compared to euthyroid controls.

Int J Endocrinol Metab. 2022; 20(3):e120949.
(with and without application of trim and fill method). No significant heterogeneity was detected among included studies investigating adverse pregnancy outcomes. Egger test showed significant publication biases only among studies investigating Hypertensive disorders (P = 0.031), adverse maternal outcomes (P = 0.001), adverse neonatal outcomes (P = 0.008), and adverse fetal outcomes (P = 0.001), which were adjusted by the trim and fill method.

There were no significant differences in pooled ORs of hypertensive disorders, preterm delivery, macrosomia/LGA, and pregnancy loss, in subclinical hyperthyroidism pregnant women, compared to the euthyroid controls group. Also, the pooled OR of adverse maternal and fetal outcomes had no statistically significant difference in subclinical hyperthyroidism compared to the euthyroid controls group with and without the trim and fill method. The Pooled OR of adverse neonatal outcomes in women with subclinical hyperthyroidism in comparison with euthyroid was 1.781 (95% CI: 1.026, 3.091); this statistically significant difference was disappeared using the trim and fill method (OR: 1.055, 95%CI: 0.597, 1.863) (Table 2).

4.3. Quality Assessment and Risk of Bias

The results of the quality assessment are accessible in Appendix 1; of 9 studies, 5 studies were classified as having good quality and 6 studies as fair quality. No studies did not identify as poor quality (Table 1 and Appendix 3).

Details of the risk of bias assessment are shown in Appendix 4. All cohort studies had a low risk of bias for selection of exposed and non-exposed cohorts, assessment of exposure, presence of outcome of interest at the start of study, outcome assessment, and adequacy of follow-up.
Figure 2. Funnel plots of pregnancy outcomes
Figure 3. Forest plots of adverse pregnancy outcomes (hypertensive disorders)

Figure 4. Forest plots of adverse pregnancy outcomes (preterm delivery)
Figure 5. Forest plots of adverse pregnancy outcomes (macrosomia)

Figure 6. Forest plots of adverse pregnancy outcomes (pregnancy loss)
of cohorts; however, 44% of studies had a high risk of bias for control of prognostic variable and 11% for assessment of the presence or absence of prognostic factors; and 22% of studies were probable high risk of bias for assessment of the absence or presence of prognostic factors (Appendix 4). In general, most of the studies included in the meta-analysis had an acceptable validity (low risk of bias), which indicates the acceptable quality of these studies in most respects.

5. Discussion

Despite existing evidence on adverse outcomes in pregnant women with overt thyroid dysfunction (21, 40-43), it is unclear whether maternal subclinical hyperthyroidism is also associated with adverse pregnancy outcomes. The current meta-analysis showed that subclinical hyperthyroidism is not associated with any adverse maternal, neonatal, and fetal outcomes.

It is well-documented that maternal subclinical hyperthyroidism, a low serum TSH but normal serum T4 and T3 concentrations, is mainly caused by mild thyroid hormone excess, but this situation may have resulted from non-thyroidal illness, excessive consumption of levothyroxine, and ingestion of drugs that inhibit TSH secretion or it may be originated from inappropriate secretion of TRH or TSH (10, 11). Presumably, maternal subclinical hyperthyroidism is a transient dysfunction during pregnancy caused by placental hormone stimulation (44); as a result, these physiological changes need to be considered, rather than being interpreted as a pathological situation. It has been well-documented that hCG has a significant thyroid-stimulating activity, which can stimulate the thyroid gland under both in vivo and in vitro. Therefore, the thyroid may be controlled twice from both hCG and TSH at the early pregnancy stage (45). The increased hCG concentration at the early pregnancy stage is associated with an increase in free thyroid hormones and a decrease in serum TSH. Notably, hCG-related pregnancy serum activity also can stimulate FRTL-5 cells, which may account for some changes in thyroid function observed during pregnancy (45). There is

---

### Table 7: Forest plots of adverse maternal outcomes

| Authors_year_country | Outcomes        | ES (95% CI)         | Weight |
|----------------------|-----------------|---------------------|--------|
| Ajmani (2013); India | Diabetes_GDM    | 19.74 (0.79, 49.1)  | 1.06   |
| Ajmani (2013); India | Placental abruption | 14.05 (0.61, 32.4) | 1.11   |
| Ajmani (2013); India | PPH             | 2.28 (0.11, 4.5)    | 1.21   |
| Ajmani (2013); India | Preeclampsia    | 1.66 (0.08, 3.0)    | 1.22   |
| Casey (2006); USA    | Diabetes_GDM    | 0.71 (0.42, 1.2)    | 13.74  |
| Casey (2006); USA    | Placental abruption | 0.75 (0.10, 5.4)   | 2.59   |
| Casey (2006); USA    | Severe Preeclampsia | 0.64 (0.38, 1.0)   | 13.75  |
| Casey (2006); USA    | PIH             | 0.66 (0.44, 0.98)   | 15.80  |
| Sahu (2010); India   | PIH             | 0.90 (0.05, 1.6)    | 1.30   |
| Sahu (2010); India   | Diabetes_GDM    | 2.22 (0.12, 4.0)    | 1.28   |
| Saki (2014); Iran    | Preeclampsia    | 2.96 (0.14, 6.3)    | 1.17   |
| Taghavi (2009); Iran | Preeclampsia    | 0.88 (0.11, 6.8)    | 2.42   |
| Wilson (2012); USA   | PIH             | 0.71 (0.50, 0.9)    | 16.79  |
| ZHOU (2019); China   | PIH             | 4.11 (0.22, 7.9)    | 1.25   |
| ZHOU (2019); China   | Diabetes_GDM    | 3.57 (0.72, 17.7)   | 3.68   |
| ZHOU (2019); China   | Placental abruption | 10.77 (0.48, 23.9) | 1.14   |
| Zhang (2019); China  | Eclampsia       | 3.79 (1.13, 12.7)   | 5.68   |
| Zhang (2019); China  | Placental abruption | 4.64 (1.04, 20.8)  | 4.11   |
| Zhang (2019); China  | PIH             | 1.29 (0.56, 3.4)    | 8.21   |
| Zhang (2019); China  | Placental previa | 1.06 (0.14, 7.9)    | 2.53   |
| Overall (I-squared = 39.3%, p = 0.037) | 1.12 (0.80, 1.58) | 100.00 |

**NOTE:** Weights are from random-effects analysis.
evidence suggesting a clear mirror image between serum levels of hCG and TSH (46). Partial or total serum TSH suppression, in association with high serum hCG levels, is a frequent finding in normal pregnancy that usually occurs as a transient feature in the late first trimester of pregnancy (46). Consequently, it leads to transient subclinical hyperthyroidism in some women (47, 48); however, this TSH suppression does not usually result in hyperthyroidism symptoms (46). Korevaar et al. found that higher hCG concentrations were associated with a higher risk of subclinical and overt hyperthyroidism (49).

Few studies have investigated adverse pregnancy outcomes in women with subclinical hyperthyroidism, with contradictory results (2, 5, 12, 26, 27, 37). In the majority of the available studies, the number of pregnant women with subclinical hyperthyroidism is small. As a result, they had inadequate power for the assessment of adverse pregnancy outcomes in this subgroup of women (3, 9, 22, 23, 37). Three meta-analyses assessed the adverse pregnancy outcomes in women with subclinical hyperthyroidism. These studies had mainly focused only on preterm delivery, IUGR, and LBW and found no significant association between subclinical hyperthyroidism and these outcomes (25, 30, 50). This meta-analysis of nine studies demonstrated that subclinical hyperthyroidism was not associated with adverse maternal outcomes, such as hypertensive disorders, preterm delivery, and pregnancy loss, neonatal outcomes, such as macrosomia/LGA, and adverse fetal outcomes. The lack of the association between subclinical hyperthyroidism and adverse pregnancy outcomes may be mainly explained by these physiological changes in thyroid hormones during pregnancy. Actually, the majority of these women had transient gestational hyperthyroidism, which might consider a physiologic condition related to pregnancy. Although there is evidence demonstrating adverse effects of excessive thyroid hormones and subclinical hyperthyroidism on the cardiovascular system in terms of increasing heart rate, carotid intima-media thickness, plasma fibrinogen levels, left ventricular mass atrial arrhythmias, impaired ventricular relaxation, and reduced exercise performance (51-55), this study showed no significant relationship between this mild maternal thyroid dysfunction and gestational hypertensive disorders.

To the best of our knowledge, this study is one of the
few meta-analyses to evaluate the association between subclinical hyperthyroidism during pregnancy and maternal, neonatal, and fetal outcomes. However, this study has several limitations that should be considered for interpreting its findings.

Firstly, various cut-off points were used to diagnose subclinical hyperthyroidism in different studies, which may affect the observed outcomes. Secondly, a limited number of publications evaluated the impact of subclinical hyperthyroidism on pregnancy outcomes compared to euthyroid pregnant women. Third, the majority of studies have not adequate statistical power due to the small number of included pregnant women with subclinical hyperthyroidism as well as the small number of adverse pregnancy outcomes. Fourth, the lack of adequate statistical power for some pregnancy outcomes limited us from running analysis for these outcomes. Fifth, TPOAb status was not determined in most of the included studies, and in studies where thyroid antibodies were measured, results were not compared to the pregnancy outcomes in subgroups of subclinical hyperthyroidism based on the TPOAb status (positive and negative) and their results were not adjusted for TPOAb status. Sixth, the iodine status and iodine supplementation have not been reported and the results were not adjusted for these variables.

Finally, the lack of adequate well-designed studies and adequate power for subgroup analysis according to the type of study or gestational age. Further studies with a large sample size among euthyroid pregnant women are necessary.

**Table 1**

| Authors_year_country | Outcomes | OR (95% CI) | % Weight |
|----------------------|----------|-------------|----------|
| Ajmani (2013); India | LBW      | 5.09 (0.25, 105.62) | 0.36 |
| Ajmani (2013); India | Preterm  | 5.09 (0.25, 105.62) | 0.36 |
| Ajmani (2013); India | IUGR/ SGA | 14.06 (0.61, 326.40) | 0.34 |
| Avramovska (2021); Switzerland | IUGR/ SGA | 1.47 (0.08, 27.69) | 0.39 |
| Avramovska (2021); Switzerland | LBW     | 1.09 (0.13, 9.35) | 0.71 |
| Casey (2006); USA    | Macrosomia | 0.78 (0.55, 1.10) | 14.02 |
| Casey (2006); USA    | LBW      | 0.99 (0.66, 1.51) | 11.45 |
| Casey (2006); USA    | Preterm  | 0.78 (0.51, 1.21) | 10.93 |
| Casey (2006); USA    | Extremely LBW | 1.61 (0.51, 5.09) | 2.34 |
| Casey (2006); USA    | preterm <34w | 0.95 (0.58, 1.56) | 9.35 |
| Mannisto (2009); N   | preterm <34w | 1.09 (0.34, 3.49) | 2.29 |
| Mannisto (2009); N   | Preterm  | 1.02 (0.52, 2.02) | 5.76 |
| Mannisto (2009); N   | LGA      | 0.59 (0.19, 1.88) | 3.33 |
| Mannisto (2009); N   | IUGR/ SGA | 15.56 (2.59, 93.66) | 1.02 |
| Mannisto (2009); N   | LBW      | 1.09 (0.50, 2.36) | 4.73 |
| Mannisto (2009); N   | Malpresentation | 0.79 (0.34, 1.80) | 4.22 |
| Sahu (2010); India   | Preterm  | 2.20 (0.12, 42.22) | 0.38 |
| Sahu (2010); India   | IUGR/ SGA | 1.81 (0.10, 33.20) | 0.40 |
| Saki (2014); Iran    | Preterm  | 1.28 (0.06, 26.86) | 0.36 |
| Saki (2014); Iran    | IUGR/ SGA | 2.96 (0.14, 63.03) | 0.36 |
| Su (2011); China     | Macrosomia | 1.38 (0.47, 4.04) | 2.66 |
| Su (2011); China     | Preterm  | 0.37 (0.02, 6.03) | 0.42 |
| Su (2011); China     | LBW      | 1.84 (0.24, 14.42) | 0.78 |
| Su (2011); China     | IUGR/ SGA | 3.00 (0.67, 13.48) | 1.43 |
| Su (2011); China     | Fetal distress | 0.69 (0.09, 5.18) | 0.81 |
| Taghavi (2009); Iran | Preterm  | 1.21 (0.15, 9.52) | 0.77 |
| ZHOU (2019); China   | Very LBW | 10.56 (1.14, 98.15) | 0.67 |
| ZHOU (2019); China   | Preterm  | 5.47 (1.32, 22.62) | 1.59 |
| ZHOU (2019); China   | PROM     | 0.31 (0.02, 5.31) | 0.41 |
| ZHOU (2019); China   | LBW      | 3.25 (0.39, 27.31) | 0.73 |
| ZHOU (2019); China   | Fetal distress | 1.81 (0.10, 32.67) | 0.40 |
| ZHOU (2019); China   | PROM     | 6.98 (1.25, 32.50) | 1.23 |
| ZHOU (2019); China   | LGA      | 0.57 (0.03, 9.95) | 0.41 |
| Zhang (2019); China  | Macrosomia | 1.24 (0.70, 2.18) | 7.60 |
| Zhang (2019); China  | Preterm  | 0.76 (0.24, 2.44) | 2.31 |
| Zhang (2019); China  | LBW      | 1.16 (0.36, 3.69) | 2.29 |
| Zhang (2019); China  | PROM     | 1.02 (0.06, 17.18) | 0.42 |
| Zhang (2019); China  | Malpresentation | 0.84 (0.31, 2.31) | 2.97 |

**Note:** Weights are from random effects analysis.
5.1. Conclusions

The current meta-analysis demonstrated that maternal subclinical hyperthyroidism is not associated with adverse maternal, neonatal, and fetal outcomes. Therefore, clinicians should be advised unnecessary treatments for pregnant women with subclinical hyperthyroidism. However, more longitudinal studies of women with subclinical hyperthyroidism with adequate power are recommended for precise interpretation of the association between this mild thyroid dysfunction and adverse pregnancy outcomes after adjusting potential confounders.

Supplementary Material

Supplementary material(s) is available here [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Acknowledgments

The authors would like to thank all authors of the primary studies included in this review.

Footnotes

Authors’ Contribution: Research idea and study design: S. N. and F. R. T.; data acquisition: S. N. and M. A.; data analysis/interpretation: S. N. and M. A.; statistical analysis: R. B. Y.; supervision: F. R. T. and F. A.; Writing, review & editing, F. R. T., and F. A. All authors have read and approved the final version for submission.

Conflict of Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data Reproducibility: The dataset presented in the study is available on request from the corresponding author during submission or after its publication.

Funding/Sponsor: No funding was received to conduct this research.

References

1. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab. 2006;91(7):2587-91. doi: 10.1210/jc.2005-4603. [PubMed: 16621810].
2. Zhang Y, Li Y, Shan Z, Xu Y, Li C, Xie X, et al. Association of Overt and Subclinical Hyperthyroidism During Weeks 4-8 with Adverse Pregnancy Outcomes. J Womens Health (Larchmt). 2019;28(6):842-8. doi: 10.1089/jwh.2018.7180. [PubMed: 30852095].
3. Ajmani SN, Aggarwal D, Bhatia P, Sharma M, Sarahbhai V, Paul M. Prevalence of overt and subclinical thyroid dysfunction among pregnant women and its effect on maternal and fetal outcome. J Obstet Gynecol India. 2014;64(2):105-10. doi: 10.1007/s12245-013-0487-y. [PubMed: 24757337]. [PubMed Central: PMC3984645].
4. Wang Y, Sun X, Wang CL, Zhang HY. Influence of screening and intervention of hyperthyroidism on pregnancy outcome. Eur Rev Med Pharmacol Sci. 2017;21(4):1932–7. [PubMed: 28249134]. [PubMed Central: PMC5605129].
5. Behrozoo HG, Tohidi M, Mehrabi Y, Behrozoo EG, Tehranidoost M, Azizi F. Subclinical hyperthyroidism in pregnancy: intellectual development of offspring. Thyroid. 2011;21(10):1443-7. doi: 10.1089/thy.2011.0053. [PubMed: 21943136]. [PubMed Central: PMC3079614].
6. Casey BM, Thom EA, Peaceman AM, Varner MW, Sorokin Y, Hirtz DG, et al. Treatment of Subclinical Hyperthyroidism or Hypothyroxinemia in Pregnancy. N Engl J Med. 2017;376(7):2185-25. doi: 10.1056/NEJMoa1606205. [PubMed: 28249134]. [PubMed Central: PMC5605129].
7. Kiran Z, Sheikh A, Malik S, Meraj A, Masood M, Iqmail S, et al. Maternal characteristics and outcomes affected by hypothyroidism during pregnancy (maternal hypothyroidism on pregnancy outcomes, MHPO-1). BMC Pregnancy Childbirth. 2019;19(7):387-96. doi: 10.1186/s12884-019-2596-9. [PubMed: 31805890]. [PubMed Central: PMC6896307].
8. Nazarpour S, Ramezani Tehrani F, Simbar M, Azizi F. Thyroid dysfunction and pregnancy outcomes. Iran J Reprod Med. 2015;13(7):387-96. [PubMed: 26494985]. [PubMed Central: PMC4609357].
9. Sahu MT, Das V, Mittal S, Agarwal A, Sahu M. Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on

---

Table 2. Results of Meta-analysis for Pregnancy Outcomes in Women with Subclinical Hyperthyroidism Compared to Euthyroid Controls (With and Without Application of Trim and Fill Method)

| Outcomes                        | P-value, Egger Test | I-squared% | Pooled Odds Ratio (95% CI) | Pooled Odds Ratio (95% CI) via Trim and Fill Method |
|---------------------------------|---------------------|------------|---------------------------|-----------------------------------------------------|
| Hypertensive disorders          | 0.031               | 33.0       | 0.839 (0.815, 1.143)       | 0.684 (0.466, 1.002)                                  |
| Preterm delivery                | 0.344               | 0.0        | 0.963 (0.759, 1.253)       |                                                     |
| Macrosomia/LGA                  | 0.847               | 0.0        | 0.885 (0.677, 1.165)       |                                                     |
| Pregnancy loss                  | 0.681               | 0.0        | 1.668 (0.728, 3.822)       |                                                     |
| Adverse maternal outcomes      | 0.001*              | 0.0        | 1.333 (0.802, 2.160)       | 0.760, 0.514, 1.123                                 |
| Adverse neonatal outcomes       | 0.008*              | 0.0        | 1.781 (1.026, 3.091)       | 1.055, 0.597, 1.863                                 |
| Adverse fetal outcomes          | 0.001*              | 0.0        | 1.095 (0.911, 1.317)       | 0.953, 0.747, 1.235                                 |

Abbreviation: LGA, large for gestational age

* Statistical significance level P < 0.05
outcome in hypothyroid pregnancies. Obstet Gynecol. 1993;81(3):349-53. [PubMed: 8437784].

43. Sheffield JS, Cunningham FG. Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol. 2004;190(1):211-7. doi: 10.1016/s0002-9378(03)00944-x. [PubMed: 14749662].

44. Pekonen F, Alfthan H, Stemman UH, Ylikorkala O. Human chorionic gonadotropin (hCG) and thyroid function in early human pregnancy: circadian variation and evidence for intrinsic thyrotropic activity of hCG. J Clin Endocrinol Metab. 1988;66(4):853-6. doi: 10.1210/jcem-66-4-853. [PubMed: 3346361].

45. Kennedy RL, Darne J. The role of hCG in regulation of the thyroid gland in normal and abnormal pregnancy. Obstet Gynecol. 1991;78(2):298-307. [PubMed: 1648698].

46. Glinoer D, De Nayer P, Robyn C, Lejeune B, Kinthaert J, Meuris S. Serum levels of intact human chorionic gonadotropin (hCG) and its free alpha and beta subunits, in relation to maternal thyroid stimulation during normal pregnancy. J Endocrinol Invest. 1993;16(11):881-8. doi: 10.1007/BF03348950. [PubMed: 791622].

47. Alemu A, Terefe B, Abebe M, Biadgo B. Thyroid hormone dysfunction during pregnancy: A review. Int J Reprod Biomed. 2016;14(11):677-86. [PubMed: 27981252]. [PubMed Central: PMC535372].

48. Okosieme OE, Marks H, Lazarus JH. Medical management of thyroid dysfunction in pregnancy and the postpartum. Expert Opin Pharmacother. 2008;9(11):2281-93. doi: 10.1517/14656566.9.13.2281. [PubMed: 18703353].

49. Korevaar TI, de Rijke YB, Chaker I, Medici M, Jaddoe VW, Steegers EA, et al. Stimulation of Thyroid Function by Human Chorionic Gonadotropin During Pregnancy: A Risk Factor for Thyroid Disease and a Mechanism for Known Risk Factors. Thyroid. 2017;27(3):440-50. doi: 10.1089/thy.2016.0527. [PubMed: 28049387].

50. Korevaar TIM, Derakhshan A, Taylor PN, Meima M, et al; Consortium on Thyroid; Pregnancy-Study Group on Preterm Birth, et al. Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. JAMA. 2019;322(7):632-41. doi: 10.1001/jama.2019.10931. [PubMed: 31429897]. [PubMed Central: PMC6704759].

51. Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep. 2003;5(6):513-20. doi: 10.1007/s11906-003-0060-7. [PubMed: 14594573].

52. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501-9. doi: 10.1056/NEJM200102153440707. [PubMed: 11172193].

53. Biondi B. Endogenous subclinical hyperthyroidism: who, when and why to treat. Expert Rev Endocrinol Metab. 2011;6(6):785-92. doi: 10.1586/erm.11.69. [PubMed: 21570289].

54. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76-131. doi: 10.1210/er.2006-0043. [PubMed: 17999805].

55. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137(11):904-14. doi: 10.7326/0003-4819-137-11-20021030-00011. [PubMed: 12458990].